Cargando…

A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma

BACKGROUND/AIMS: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hee Yeon, Kim, Jin Dong, Bae, Si Hyun, Park, Jun Yong, Han, Kwang Hyub, Woo, Hyun Young, Choi, Jong Young, Yoon, Seung Kew, Jang, Byoung Kuk, Hwang, Jae Seok, Kim, Sang Gyune, Kim, Young Seok, Seo, Yeon Seok, Yim, Hyung Joon, Um, Soon Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304604/
https://www.ncbi.nlm.nih.gov/pubmed/21415578
http://dx.doi.org/10.3350/kjhep.2010.16.4.355
_version_ 1782226912800669696
author Kim, Hee Yeon
Kim, Jin Dong
Bae, Si Hyun
Park, Jun Yong
Han, Kwang Hyub
Woo, Hyun Young
Choi, Jong Young
Yoon, Seung Kew
Jang, Byoung Kuk
Hwang, Jae Seok
Kim, Sang Gyune
Kim, Young Seok
Seo, Yeon Seok
Yim, Hyung Joon
Um, Soon Ho
author_facet Kim, Hee Yeon
Kim, Jin Dong
Bae, Si Hyun
Park, Jun Yong
Han, Kwang Hyub
Woo, Hyun Young
Choi, Jong Young
Yoon, Seung Kew
Jang, Byoung Kuk
Hwang, Jae Seok
Kim, Sang Gyune
Kim, Young Seok
Seo, Yeon Seok
Yim, Hyung Joon
Um, Soon Ho
author_sort Kim, Hee Yeon
collection PubMed
description BACKGROUND/AIMS: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. METHODS: The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m(2) on days 1~3) and cisplatin (60 mg/m(2) on day 2 every 4 weeks) via an implantable port system. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. RESULTS: Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. CONCLUSIONS: High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC.
format Online
Article
Text
id pubmed-3304604
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-33046042012-03-20 A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma Kim, Hee Yeon Kim, Jin Dong Bae, Si Hyun Park, Jun Yong Han, Kwang Hyub Woo, Hyun Young Choi, Jong Young Yoon, Seung Kew Jang, Byoung Kuk Hwang, Jae Seok Kim, Sang Gyune Kim, Young Seok Seo, Yeon Seok Yim, Hyung Joon Um, Soon Ho Korean J Hepatol Original Article BACKGROUND/AIMS: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. METHODS: The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m(2) on days 1~3) and cisplatin (60 mg/m(2) on day 2 every 4 weeks) via an implantable port system. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. RESULTS: Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. CONCLUSIONS: High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC. The Korean Association for the Study of the Liver 2010-12 2010-12-31 /pmc/articles/PMC3304604/ /pubmed/21415578 http://dx.doi.org/10.3350/kjhep.2010.16.4.355 Text en Copyright © 2010 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Hee Yeon
Kim, Jin Dong
Bae, Si Hyun
Park, Jun Yong
Han, Kwang Hyub
Woo, Hyun Young
Choi, Jong Young
Yoon, Seung Kew
Jang, Byoung Kuk
Hwang, Jae Seok
Kim, Sang Gyune
Kim, Young Seok
Seo, Yeon Seok
Yim, Hyung Joon
Um, Soon Ho
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma
title A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma
title_full A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma
title_fullStr A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma
title_full_unstemmed A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma
title_short A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma
title_sort comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304604/
https://www.ncbi.nlm.nih.gov/pubmed/21415578
http://dx.doi.org/10.3350/kjhep.2010.16.4.355
work_keys_str_mv AT kimheeyeon acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT kimjindong acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT baesihyun acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT parkjunyong acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT hankwanghyub acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT woohyunyoung acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT choijongyoung acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT yoonseungkew acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT jangbyoungkuk acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT hwangjaeseok acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT kimsanggyune acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT kimyoungseok acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT seoyeonseok acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT yimhyungjoon acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT umsoonho acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT acomparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT kimheeyeon comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT kimjindong comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT baesihyun comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT parkjunyong comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT hankwanghyub comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT woohyunyoung comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT choijongyoung comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT yoonseungkew comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT jangbyoungkuk comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT hwangjaeseok comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT kimsanggyune comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT kimyoungseok comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT seoyeonseok comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT yimhyungjoon comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT umsoonho comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma
AT comparativestudyofhighdosehepaticarterialinfusionchemotherapyandtransarterialchemoembolizationusingdoxorubicinforintractableadvancedhepatocellularcarcinoma